DAH

3,4-DIHYDROXYPHENYLALANINE

Created:	1999-07-08
Last modified:	2024-09-27

Find Related PDB Entry
7 entries where DAH is found as a standalone ligand24 entries where DAH is found in a polymer sequence

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	25
Chiral Atom Count	1
Bond Count	25
Aromatic Bond Count	6

WebGL does not seem to be available.

This can be caused by an outdated browser, graphics card driver issue, or bad weather. Sometimes, just restarting the browser helps. Also, make sure hardware acceleration is enabled in your browser.

For a list of supported browsers, refer to http://caniuse.com/#feat=webgl.

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	3,4-DIHYDROXYPHENYLALANINE
Synonyms	L-DOPA
Systematic Name (OpenEye OEToolkits)	(2S)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid
Formula	C₉ H₁₁ N O₄
Molecular Weight	197.188
Type	L-PEPTIDE LINKING

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	O=C(O)C(N)Cc1cc(O)c(O)cc1
SMILES	CACTVS	3.370	N[CH](Cc1ccc(O)c(O)c1)C(O)=O
SMILES	OpenEye OEToolkits	1.7.2	c1cc(c(cc1CC(C(=O)O)N)O)O
Canonical SMILES	CACTVS	3.370	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O
Canonical SMILES	OpenEye OEToolkits	1.7.2	c1cc(c(cc1C[C@@H](C(=O)O)N)O)O
InChI	InChI	1.03	InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
InChIKey	InChI	1.03	WTDRDQBEARUVNC-LURJTMIESA-N

Drug Info: DrugBank

DrugBank ID	DB01235
Name	Levodopa
Groups	approved
Description	Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Synonyms	3,4-Dihydroxy-L-phenylalanine L-DOPA β-(3,4-dihydroxyphenyl)-L-alanine Dihydroxy-L-phenylalanine Levodopum L-beta-(3,4-Dihydroxyphenyl)alanine (−)-3-(3,4-dihydroxyphenyl)-L-alanine 3-Hydroxy-L-tyrosine Levodopa β-(3,4-dihydroxyphenyl)alanine L-3,4-dihydroxyphenylalanine (−)-dopa
Brand Names	Levodopa-carbidopa Sinemet CR 100/25 Dom-levo-carbidopa Dhivy Apo-levocarb Mint-levocarb Teva-levocarbidopa Carbidopa, levodopa and entacapone Pro-lecarb-100/25 - Tab Prolopa Cap 200-50 Parcopa Prolopa Cap 50-12.5 Pro-levocarb - 100/25 Corbilta Levodopa-carbidopa CR Numient Carbidopa, Levodopa and Entacapone Sandoz Levodopa-carbidopa-entacapone Sinemet Carbidopa-levodopa Prolopa Cap 100-25 Rytary Auro-levocarb Duopa Carbidopa and Levodopa Aa-levocarb CR Inbrija Pro-lecarb-100/10 - Tab Duodopa Crexont Carbidopa and levodopa Jamp Levocarb Levodopa, Carbidopa and Entacapone Tablets Sinemet 100/10 PMS-levodopa-carbidopa Stalevo Ag-levocarb Carbidopa, Levodopa, and Entacapone Levodopa/carbidopa/entacapone Orion Sinemet CR 200/50 Sinemet CR Ratio-levodopa/carbidopa
Indication	Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa[FDA Label]. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism following carbon monoxide intoxication or manganese intoxication[F4579].
Categories	Amines Amino Acids Amino Acids, Aromatic Amino Acids, Cyclic Amino Acids, Peptides, and Proteins Anti-Dyskinesia Agents Anti-Parkinson Agents (Dopamine Agonist) Anti-Parkinson Drugs Benzene Derivatives Biogenic Amines Biogenic Monoamines Catecholamines Catechols Central Nervous System Agents Central Nervous System Depressants Dihydroxyphenylalanine Dopa and Dopa Derivatives Dopamine Agents Hypotensive Agents Levodopa, antagonists & inhibitors Nervous System Neurotransmitter Agents Phenols Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
ATC-Code	N04BA03 N04BA01 N04BA02
CAS number	59-92-7

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
D(1A) dopamine receptor	MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIR...	unknown	agonist
D(1B) dopamine receptor	MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLL...	unknown	agonist
D(2) dopamine receptor	MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF...	unknown	agonist
D(3) dopamine receptor	MASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV...	unknown	agonist
D(4) dopamine receptor	MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLA...	unknown	agonist
Aromatic-L-amino-acid decarboxylase	MNASEFRRRGKEMVDYMANYMEGIEGRQVYPDVEPGYLRPLIPAAAPQEP...	unknown	substrate
Albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
Solute carrier family 15 member 1	MGMSKSHSFFGYPLSIFFIVVNEFCERFSYYGMRAILILYFTNFISWDDN...	unknown	inhibitor
Monocarboxylate transporter 10	MVLSQEEPDSARGTSEAQPLGPAPTGAAPPPGPGPSDSPEAAVEKVEVEL...	unknown	inhibitor
Large neutral amino acids transporter small subunit 1	MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNI...	unknown
Large neutral amino acids transporter small subunit 2	MEEGARHRNNTEKKHPGGGESDASPEAGSGGGGVALKKEIGLVSACGIIV...	unknown
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682